Affiliate disclosure: As an Amazon Associate, this site earns from qualifying purchases linked in this article.
As women navigate the perimenopausal transition, many experience changes in their intimate health, including vaginal dryness. This symptom is often part of a broader set of changes known as genitourinary syndrome of menopause (GSM), which can affect the vulva, vagina, and lower urinary tract [1]. These changes are primarily linked to declining estrogen levels, leading to thinning, less elastic, and drier vaginal tissues.
For those seeking targeted support for vaginal dryness during perimenopause, localized DHEA (dehydroepiandrosterone) has emerged as an area of interest. This article will explore the current understanding of how DHEA may offer a focused approach to addressing these intimate health concerns, drawing on available research.
Understanding Vaginal Dryness in Perimenopause and Genitourinary Syndrome of Menopause (GSM)
Vaginal dryness is a common and often bothersome symptom for women in perimenopause and beyond. It can contribute to discomfort, itching, irritation, and painful intercourse (dyspareunia) [2]. These symptoms are components of genitourinary syndrome of menopause (GSM), a term that encompasses various changes in the genitourinary system due to reduced estrogen [1]. The vaginal tissues become thinner, less lubricated, and less elastic, impacting overall vaginal health and sexual function [2].
While systemic hormone therapy can address GSM, not all women are candidates or prefer this approach. This has led to an increased focus on localized therapies that can specifically target vaginal symptoms without significant systemic absorption, offering a more focused strategy for intimate health concerns [3].
How Localized DHEA May Support Vaginal Health
Localized DHEA, typically administered as a vaginal insert, is a steroid precursor that is converted into sex steroids, including estrogens and androgens, directly within the vaginal cells [4]. This localized conversion is thought to help rejuvenate the vaginal tissues by promoting cell proliferation and improving hydration, elasticity, and lubrication [4]. The benefit of this targeted approach is that it aims to provide the necessary support to the vaginal tissues with minimal systemic DHEA absorption, which is often a consideration for women seeking localized options [5].
This mechanism allows for a focused action where it’s needed most, potentially addressing the underlying tissue changes associated with vaginal dryness and discomfort during perimenopause [4].
Evidence for DHEA and Vaginal Dryness in Perimenopause
Research has explored the potential of intravaginal DHEA for symptoms related to vaginal dryness and atrophy. A systematic review noted that intravaginal DHEA has shown efficacy for symptomatic women in the peri- or postmenopausal phase [5]. Another review highlighted that vaginal DHEA can be an effective option for treating menopause-related atrophy [4].
Further systematic reviews have identified intravaginal DHEA as an effective hormonal approach for vaginal atrophy and sexual dysfunctions in postmenopausal women [6]. The North American Menopause Society’s position statement also includes vaginal DHEA as a therapeutic option for genitourinary syndrome of menopause [1]. These findings suggest a consistent pattern of evidence supporting the use of localized DHEA for these specific concerns.
While much of the research focuses on postmenopausal women, the mechanisms and benefits for vaginal tissue health are also relevant for women experiencing similar changes during perimenopause. Studies have indicated that intravaginal DHEA can improve various aspects of vulvovaginal atrophy, including vaginal dryness, discomfort, and painful intercourse [7].
Comparing DHEA to Other Non-Estrogen Approaches
For women who cannot or prefer not to use estrogen-based therapies, non-estrogen options are increasingly important. A systematic review on nonestrogen therapies for genitourinary syndrome of menopause included intravaginal DHEA as a relevant option [3]. Other non-hormonal approaches include vaginal moisturizers and lubricants, which provide temporary relief but do not address the underlying tissue changes [8].
DHEA offers a distinct approach by working within the vaginal cells to produce local sex steroids, potentially offering more sustained improvements in tissue health compared to symptomatic relief from moisturizers alone [4]. This makes it a consideration for women seeking a more targeted and comprehensive approach beyond basic lubrication.
References
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause (New York, N.Y.), 2020
- Female Pelvic Conditions: Genitourinary Syndrome of Menopause. FP essentials, 2022
- Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review. Obstetrics and gynecology, 2023
- Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas, 2011
- Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase. Maturitas, 2018
- Efficacy of Hormonal and Nonhormonal Approaches to Vaginal Atrophy and Sexual Dysfunctions in Postmenopausal Women: A Systematic Review. Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2022
- Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient?. Post reproductive health, 2022
- New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review. Medicina (Kaunas, Lithuania), 2022
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
